Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

被引：160

作者：

Pfaller, Michael A. ^{[1
]}

Moet, Gary J. ^{[1
]}

Messer, Shawn A. ^{[1
]}

Jones, Ronald N. ^{[1
,2
]}

Castanheira, Mariana ^{[1
]}

机构：

[1] JMI Labs, N Liberty, IA 52317 USA

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2011年 / 49卷 / 01期

关键词：

INVASIVE CANDIDIASIS; CASPOFUNGIN RESISTANCE; GLABRATA; SUSCEPTIBILITY; VORICONAZOLE; MICAFUNGIN; EPIDEMIOLOGY; FLUCONAZOLE; BREAKPOINTS; SECONDARY;

D O I：

10.1128/JCM.01398-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Antifungal testing results from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) were analyzed for regional variations of invasive Candida species infections. Among 2,085 cases from the Asian-Pacific (APAC) (51 cases), Latin American (LAM) (348 cases), European (EU) (750 cases), and North American (NAM) (936 cases) regions, Candida albicans predominated (48.4%), followed by C. glabrata (18.0%), C. parapsilosis (17.2%), C. tropicalis (10.5%), and C. krusei (1.9%). Resistance to echinocandins (anidulafungin [2.4%] and micafungin [1.9%]) and azoles (3.5 to 5.6%) was most prevalent among C. glabrata isolates, as determined using recently established CLSI breakpoint criteria. C. glabrata isolates were more common in NAM (23.5%), and C. albicans isolates were more common in APAC (56.9%), with C. parapsilosis (25.6%) and C. tropicalis (17.0%) being more prominent in LAM. Emerging resistance patterns among C. glabrata cases in NAM require focused surveillance.

引用

页码：396 / 399

页数：4

共 22 条

[1] Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazol
Alexander, BD
Schell, WA
Miller, JL
Long, GD
Perfect, JR
[J]. TRANSPLANTATION, 2005, 80 (06) : 868 - 871
[2] Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient
Chapeland-Leclerc, Florence
Hennequin, Christophe
Papon, Nicolas
Noel, Thierry
Girard, Aurelie
Socie, Gerard
Ribaud, Patricia
Lacroix, Claire
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) : 1360 - 1362
[3] Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during Candidemia treatment
Cleary, John D.
Garcia-Effron, Guillermo
Chapman, Stanley W.
Perlin, David S.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (06) : 2263 - 2265
[4] CLSI, 2008, REF METH BROTH DIL A, V28
[5] CLSI, 2008, REFERENCE METHOD BRO
[6] A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
Diekema, Daniel J.
Messer, Shawn A.
Hollis, Richard J.
Boyken, Linda
Tendolkar, Shailesh
Kroeger, Jennifer
Jones, Ronald N.
Pfaller, Michael A.
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 63 (02) : 233 - 236
[7] Dodgson KJ, 2005, CLIN MICROBIOL INFEC, V11, P364
[8] Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
Garcia-Effron, Guillermo
Chua, Daniel Joseph
Tomada, Jon Rupert
DiPersio, Joseph
Perlin, David S.
Ghannoum, Mahmoud
Bonilla, Hector
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 2225 - 2227
[9] International surveillance of Candida spp. and Aspergillus spp.:: Report from the SENTRY Antimicrobial Surveillance Program (2003)
Messer, Shawn A.
Jones, Ronald N.
Fritsche, Thomas R.
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (05) : 1782 - 1787
[10] Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
Oxman, David A.
Chow, Jennifer K.
Frendl, Gyorgy
Hadley, Susan
Hershkovitz, Shay
Ireland, Peter
McDermott, Laura A.
Tsai, Katy
Marty, Francisco M.
Kontoyiannis, Dimitrios P.
Golan, Yoav
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (07) : 1460 - 1465

← 1 2 3 →